Immunomedics In Software Project With Ideagen To Streamline Document Reviews Of Cancer Treatment Processes

Ideagen’s PleaseReview will improve review, co-authoring and redaction projects linked to cancer and other oncology treatments

US-based pharmaceutical company, Immunomedics, is to work with Ideagen in a software project designed to enhance processes associated with cancer and other oncology treatments.

Immunomedics will implement Ideagen’s PleaseReview product to improve its regulatory and process-driven documentation review projects.

More than 300 Immunomedics’ staff are involved in the creation, review, co-authoring and redaction processes of critical documentation linked to oncology treatments, specifically cancers.

Now review projects – which can involve anything up to 50 authors and reviewers at any one time – will be managed centrally and electronically via Ideagen’s software.

Kiyoung Hong, Director of Regulatory Operations and Publishing at Immunomedics, said: “PleaseReview will be an extremely beneficial system for us as we look to streamline and improve our entire document creation and review processes.

“These projects can be quite intense and time-consuming, with sometimes up to 50 authors and reviewers involved at any one time.

“PleaseReview will significantly simplify this process, reducing overall review times and making it easier and quicker for often crucial pieces of documentation to be completed and signed off.”

Focussing on the development of antibody-drug conjugates for the treatment of cancers, Immunomedics create and review several types of documentation as part of their day-to-day work. These include;

  • Regulatory
  • Clinical
  • Chemistry, Manufacturing and Controls (CMC) Regulatory Affairs

Mr. Hong added: “Initially, PleaseReview will be used for our regulatory submission documents but over time it will be our system for organisation-wide document reviews.”

Martin Joynes, Ideagen’s Product Manager for PleaseReview, said: “This is a fantastic project for Ideagen. We are excited to be working with such a large, ambitious and growing pharmaceutical company in the form of Immunomedics.

“This is yet another outstanding testament to the capabilities of our PleaseReview software. It is gratifying that PleaseReview is contributing to the vision of creating and delivering breakthrough therapies for hard to treat cancers, transforming patients’ lives.

“We are delighted to welcome Immunomedics to the Ideagen community.”

PleaseReview is Ideagen’s document review, co-authoring and redaction software application that helps organisations control and manage all aspects of the document creation and review process.

The software is used by more than 300 clients globally.

www.ideagen.com
www.ideagen.com/products/pleasereview
www.immunomedics.com

Joe O’Brien
PR & Media Relations
Ideagen

+44 (0) 1629 699100
+44 (0) 7916 131501
joseph.obrien@ideagen.com

user

Recent Posts

UOG (United One Group) Wins Three Prestigious Industry Awards at CES 2026

CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…

6 hours ago

Best Ipamorelin vs Sermorelin: Growth Hormone Peptide Comparison 2026 — ReadyRx Prescription Telehealth Analysis

Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…

9 hours ago

GLP-1 Booster From Health Journey: 2026 Ingredient Analysis And Probiotic Metabolic Support Explained

Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…

9 hours ago

MEDVi GLP-1 Investigation: What Consumer Data Shows About Compounded Telehealth Weight Loss Programs

Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…

9 hours ago

Best Peptides for Anti-Aging: NAD+ Delivery Methods Compared as Telehealth Platforms Expand Access (2026 Analysis)

Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access…

9 hours ago

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a…

9 hours ago